DE69726724D1 - Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen - Google Patents
Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungenInfo
- Publication number
- DE69726724D1 DE69726724D1 DE69726724T DE69726724T DE69726724D1 DE 69726724 D1 DE69726724 D1 DE 69726724D1 DE 69726724 T DE69726724 T DE 69726724T DE 69726724 T DE69726724 T DE 69726724T DE 69726724 D1 DE69726724 D1 DE 69726724D1
- Authority
- DE
- Germany
- Prior art keywords
- neurological disorders
- pyridylpiperazine
- tetrahydropteridine
- treatment
- crf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1819896P | 1996-05-23 | 1996-05-23 | |
US18198P | 1996-05-23 | ||
PCT/US1997/008448 WO1997044038A1 (en) | 1996-05-23 | 1997-05-19 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69726724D1 true DE69726724D1 (de) | 2004-01-22 |
DE69726724T2 DE69726724T2 (de) | 2004-12-09 |
Family
ID=21786748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69726724T Expired - Fee Related DE69726724T2 (de) | 1996-05-23 | 1997-05-19 | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen |
Country Status (14)
Country | Link |
---|---|
US (3) | US6083948A (de) |
EP (1) | EP0901374B1 (de) |
JP (1) | JP2000511183A (de) |
AT (1) | ATE255896T1 (de) |
AU (1) | AU739269B2 (de) |
CA (1) | CA2255650A1 (de) |
DE (1) | DE69726724T2 (de) |
DK (1) | DK0901374T3 (de) |
ES (1) | ES2213216T3 (de) |
IL (1) | IL127170A0 (de) |
NZ (1) | NZ332704A (de) |
PT (1) | PT901374E (de) |
WO (1) | WO1997044038A1 (de) |
ZA (1) | ZA973884B (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69903333T2 (de) * | 1998-11-12 | 2003-08-07 | Neurocrine Biosciences, Inc. | Crf rezeptor-antagonisten und darauf bezogene methoden |
KR20010080402A (ko) * | 1998-11-12 | 2001-08-22 | 추후기재 | Crf 수용체 길항제 및 그와 관련된 방법 |
US6531475B1 (en) * | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
EP1040831A3 (de) * | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Verwendung von Corticotropin Releasing Factor (CRF) Antagonisten zur Prophylaxe des plötzlichen Todes |
US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
EP1224187B1 (de) * | 1999-09-30 | 2006-02-22 | Neurogen Corporation | Einige alkylendiamin-substituierte heterocyclen |
TWI271406B (en) * | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
WO2001083486A1 (en) * | 2000-05-01 | 2001-11-08 | Bristol-Myers Squibb Pharma Company | Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists |
WO2001087892A1 (en) * | 2000-05-18 | 2001-11-22 | Neurocrine Biosciences, Inc. | Crf receptor antagonists |
IL153264A0 (en) * | 2000-07-19 | 2003-07-06 | Bristol Myers Squibb Co | A compound having corticotropin releasing factor receptor ligand activity and pharmaceutical compositions containing the same |
ATE521353T1 (de) * | 2000-10-23 | 2011-09-15 | Glaxosmithkline Llc | Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten |
HUP0304035A2 (hu) * | 2001-04-30 | 2004-04-28 | Glaxo Group Limited | Kortikotropin-releasing faktor (CRF) receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
HUP0400854A2 (hu) * | 2001-05-21 | 2004-08-30 | Neurocrine Inc. | Tri- és tetraaza-acenaftilén-származékok mint CRF receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények |
AU2003225072A1 (en) * | 2002-04-19 | 2003-11-03 | Smithkline Beecham Corporation | Novel compounds |
US7067658B2 (en) | 2002-09-30 | 2006-06-27 | Bristol-Myers Squibb Company | Pyridino and pyrimidino pyrazinones |
US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
EP1846410B1 (de) * | 2005-02-10 | 2009-01-21 | Bristol-Myers Squibb Company | Dihydrochinazolinone als 5ht-modulatoren |
CA2614223A1 (en) * | 2005-02-24 | 2006-08-31 | Dr Pharma Nova, Llc | A registry method and control system for dea schedule ii-v medicines |
TWI389690B (zh) | 2005-03-25 | 2013-03-21 | Glaxo Group Ltd | 新穎化合物(一) |
US7423042B2 (en) * | 2005-03-25 | 2008-09-09 | Glaxo Group Limited | Compounds |
JP2008537937A (ja) * | 2005-03-25 | 2008-10-02 | グラクソ グループ リミテッド | ピリド[2,3−d]ピリミジン−7−オンおよび3,4−ジヒドロピリミド[4,5−d]ピリミジン−2(1H)−オン誘導体の製造方法 |
PE20100741A1 (es) * | 2005-03-25 | 2010-11-25 | Glaxo Group Ltd | COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38 |
EA200800430A1 (ru) * | 2005-07-28 | 2008-06-30 | Бристол-Маерс Сквибб Компани | Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов |
US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
ES2381212T3 (es) | 2006-04-12 | 2012-05-24 | Vertex Pharmaceuticals Incorporated | 4,5-Dihidro-[1,2,4]triazolo[4,3-F]pteridinas como inhibidores de la proteincinasa PLK1 para el tratamiento de trastornos proliferativos |
WO2007148064A1 (en) * | 2006-06-23 | 2007-12-27 | Astrazeneca Ab | Pteridine derivatives and their use as cathespin inhibitors |
JP4654325B2 (ja) | 2008-04-15 | 2011-03-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 3−フェニルピラゾロ[5,1−b]チアゾール化合物 |
CN103497192B (zh) | 2008-12-09 | 2015-09-23 | 吉里德科学公司 | Toll样受体调节剂 |
WO2010096426A2 (en) * | 2009-02-20 | 2010-08-26 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
SI2477987T1 (en) | 2009-09-14 | 2018-03-30 | Gilead Sciences, Inc. | MODULATORS TO TOLL OF LIKE RECEPTORS |
JP2013505927A (ja) | 2009-09-25 | 2013-02-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピリミジン誘導体の調製方法 |
EP2480553A2 (de) | 2009-09-25 | 2012-08-01 | Vertex Pharmaceuticals Incorporated | Verfahren zur herstellung von als proteinkinasehemmer geeigneten pyrimidinderivaten |
CA2799986C (en) | 2010-06-10 | 2017-03-07 | Union Carbide Chemicals & Plastics Technology Llc | Thiobis phenolic antioxidant/polyethylene glycol blends |
US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
KR102019810B1 (ko) | 2011-05-20 | 2019-09-10 | 유니온 카바이드 케미칼즈 앤드 플라스틱스 테크날러지 엘엘씨 | 티오비스 페놀계 항산화제/폴리에틸렌 글리콜 블렌드 |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2016007765A1 (en) | 2014-07-11 | 2016-01-14 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
JP6604664B2 (ja) | 2014-08-04 | 2019-11-13 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
UY36298A (es) | 2014-09-16 | 2016-04-29 | Gilead Science Inc | Formas sólidas de un modulador del receptor tipo toll |
ES2975520T3 (es) | 2014-09-16 | 2024-07-08 | Gilead Sciences Inc | Métodos de preparación de productos intermedios para moduladores de receptores tipo peaje |
DK3325490T3 (da) | 2015-07-23 | 2020-02-03 | Takeda Pharmaceuticals Co | 1-substituerede 1,2,3,4-tetrahydro-1,7-naphthyridin-8-aminderivater og deres anvendelse som ep4-receptorantagonister |
WO2017056115A1 (en) * | 2015-10-03 | 2017-04-06 | Sun Pharma Advanced Research Company Limited | Novel n-aryl containing fused heterocyclic compounds |
EP3696181A1 (de) | 2015-11-20 | 2020-08-19 | Forma Therapeutics, Inc. | Purinone als ubiquitinspezifische protease-1-inhibitoren |
AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
MX2022012259A (es) | 2020-03-31 | 2022-12-08 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
CA3174252A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3127402A (en) * | 1964-03-31 | Y-oxopteridine derivatives | ||
US4077955A (en) * | 1977-02-17 | 1978-03-07 | E. R. Squibb & Sons, Inc. | Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters |
EP0008864A1 (de) * | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazin- und Chinoxalinderivate, Verfahren zu ihrer Herstellung, und sie enthaltende pharmazeutische Zusammensetzungen |
FI823156L (fi) * | 1981-09-16 | 1983-03-17 | Ciba Geigy Ag | Foerfarande foer framstaellning av nya polycykliska polyazaheterocykler |
US4510141A (en) * | 1982-09-13 | 1985-04-09 | Ciba-Geigy Corporation | Tricyclic polyazaheterocycles for treating depression or anxiety |
GB8318833D0 (en) * | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
JPS5976086A (ja) * | 1982-09-20 | 1984-04-28 | ザ ウエルカム フアウンデ−シヨン リミテツド | プテリジン化合物 |
JP2550456B2 (ja) | 1990-11-06 | 1996-11-06 | 山之内製薬株式会社 | 縮合ピラジン誘導体 |
US5198547A (en) * | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
TW274550B (de) * | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
NZ284143A (en) * | 1994-06-06 | 1999-01-28 | Pfizer | Susbstituted pyrazoles having corticotropin-releasing factor (crf) antagonist activity |
TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
MX9606504A (es) | 1994-06-16 | 1997-03-29 | Pfizer | Compuestos biciclicos. |
JP3273108B2 (ja) * | 1994-09-21 | 2002-04-08 | アサヒビール株式会社 | 新規ピリド〔2,3−d〕ピリミジン誘導体及びその製造方法 |
-
1997
- 1997-05-06 ZA ZA973884A patent/ZA973884B/xx unknown
- 1997-05-16 US US08/857,349 patent/US6083948A/en not_active Expired - Lifetime
- 1997-05-19 WO PCT/US1997/008448 patent/WO1997044038A1/en active IP Right Grant
- 1997-05-19 DK DK97926590T patent/DK0901374T3/da active
- 1997-05-19 EP EP97926590A patent/EP0901374B1/de not_active Expired - Lifetime
- 1997-05-19 DE DE69726724T patent/DE69726724T2/de not_active Expired - Fee Related
- 1997-05-19 NZ NZ332704A patent/NZ332704A/xx unknown
- 1997-05-19 ES ES97926590T patent/ES2213216T3/es not_active Expired - Lifetime
- 1997-05-19 CA CA002255650A patent/CA2255650A1/en not_active Abandoned
- 1997-05-19 PT PT97926590T patent/PT901374E/pt unknown
- 1997-05-19 JP JP09542618A patent/JP2000511183A/ja active Pending
- 1997-05-19 AT AT97926590T patent/ATE255896T1/de not_active IP Right Cessation
- 1997-05-19 IL IL12717097A patent/IL127170A0/xx unknown
- 1997-05-19 AU AU31316/97A patent/AU739269B2/en not_active Ceased
-
2000
- 2000-05-11 US US09/570,775 patent/US6399609B1/en not_active Expired - Lifetime
-
2002
- 2002-01-29 US US10/059,910 patent/US6869955B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
NZ332704A (en) | 2000-05-26 |
DE69726724T2 (de) | 2004-12-09 |
ATE255896T1 (de) | 2003-12-15 |
EP0901374A4 (de) | 2001-05-09 |
AU739269B2 (en) | 2001-10-11 |
JP2000511183A (ja) | 2000-08-29 |
EP0901374B1 (de) | 2003-12-10 |
DK0901374T3 (da) | 2004-04-05 |
CA2255650A1 (en) | 1997-11-27 |
IL127170A0 (en) | 1999-09-22 |
US6399609B1 (en) | 2002-06-04 |
ZA973884B (en) | 1998-11-06 |
US6869955B2 (en) | 2005-03-22 |
US6083948A (en) | 2000-07-04 |
WO1997044038A1 (en) | 1997-11-27 |
AU3131697A (en) | 1997-12-09 |
ES2213216T3 (es) | 2004-08-16 |
EP0901374A1 (de) | 1999-03-17 |
US20030064993A1 (en) | 2003-04-03 |
PT901374E (pt) | 2004-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE255896T1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
PT1049699E (pt) | Pirazolotriazinas como antagonistas de flc | |
BR9307646A (pt) | Pirrolopirimidinas como antagonistas de crf | |
LV12262A (lv) | Ar arilaminu kondenseti piridini un pirimidini | |
ATE313326T1 (de) | VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß | |
ATE225176T1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
ATE213495T1 (de) | Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper | |
DE69936335D1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
ATE267013T1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit | |
DE69524623D1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
DE69936779D1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
ATE225181T1 (de) | Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen | |
ATE209910T1 (de) | Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen | |
EP1380298A3 (de) | Tetrahydropteridines und Pyridylpiperazine zur Behandlung von neurologischen Krankheiten, Anorexia, Entzündungen | |
TR200101476T2 (tr) | N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması | |
MY141752A (en) | Pyrazolotriazines as crf antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |